|
Organogénesis Holdings Inc. (ORGO) Valoración de DCF
US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Organogenesis Holdings Inc. (ORGO) Bundle
¿Busca evaluar el valor intrínseco de Organogénesis Holdings Inc.? Nuestra calculadora (Orgo) DCF fusiona datos del mundo real con extensas características de personalización, lo que le permite refinar sus pronósticos y mejorar sus opciones de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 261.0 | 338.3 | 468.1 | 450.9 | 433.1 | 498.5 | 573.8 | 660.4 | 760.1 | 874.8 |
| Revenue Growth, % | 0 | 29.63 | 38.36 | -3.67 | -3.94 | 15.09 | 15.09 | 15.09 | 15.09 | 15.09 |
| EBITDA | -21.9 | 37.2 | 87.0 | 40.3 | 36.0 | 38.4 | 44.1 | 50.8 | 58.5 | 67.3 |
| EBITDA, % | -8.38 | 11 | 18.59 | 8.94 | 8.32 | 7.69 | 7.69 | 7.69 | 7.69 | 7.69 |
| Depreciation | 9.4 | 8.2 | 16.7 | 18.0 | 23.4 | 19.0 | 21.8 | 25.1 | 28.9 | 33.3 |
| Depreciation, % | 3.61 | 2.42 | 3.56 | 4 | 5.41 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 |
| EBIT | -31.3 | 29.0 | 70.3 | 22.3 | 12.6 | 19.4 | 22.3 | 25.7 | 29.6 | 34.0 |
| EBIT, % | -12 | 8.59 | 15.02 | 4.94 | 2.9 | 3.89 | 3.89 | 3.89 | 3.89 | 3.89 |
| Total Cash | 60.2 | 84.4 | 113.9 | 102.5 | 104.3 | 118.8 | 136.7 | 157.4 | 181.1 | 208.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 39.4 | 56.8 | 82.5 | 89.5 | 82.0 | 88.0 | 101.3 | 116.6 | 134.2 | 154.4 |
| Account Receivables, % | 15.08 | 16.79 | 17.62 | 19.84 | 18.93 | 17.65 | 17.65 | 17.65 | 17.65 | 17.65 |
| Inventories | 22.9 | 27.8 | 25.0 | 24.8 | 28.3 | 34.3 | 39.4 | 45.4 | 52.2 | 60.1 |
| Inventories, % | 8.78 | 8.22 | 5.35 | 5.5 | 6.52 | 6.87 | 6.87 | 6.87 | 6.87 | 6.87 |
| Accounts Payable | 28.4 | 23.4 | 29.3 | 32.3 | 30.7 | 38.2 | 44.0 | 50.6 | 58.3 | 67.0 |
| Accounts Payable, % | 10.88 | 6.91 | 6.27 | 7.17 | 7.09 | 7.66 | 7.66 | 7.66 | 7.66 | 7.66 |
| Capital Expenditure | -6.2 | -21.1 | -31.2 | -33.9 | -24.4 | -28.4 | -32.6 | -37.6 | -43.3 | -49.8 |
| Capital Expenditure, % | -2.39 | -6.25 | -6.67 | -7.52 | -5.62 | -5.69 | -5.69 | -5.69 | -5.69 | -5.69 |
| Tax Rate, % | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 |
| EBITAT | -31.4 | 27.1 | 103.9 | 17.1 | 6.0 | 16.2 | 18.6 | 21.5 | 24.7 | 28.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -62.1 | -13.2 | 72.4 | -2.6 | 7.4 | 2.3 | -4.9 | -5.6 | -6.5 | -7.4 |
| WACC, % | 10.33 | 10.27 | 10.33 | 10.1 | 9.82 | 10.17 | 10.17 | 10.17 | 10.17 | 10.17 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -15.1 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | -8 | |||||||||
| Terminal Value | -115 | |||||||||
| Present Terminal Value | -71 | |||||||||
| Enterprise Value | -86 | |||||||||
| Net Debt | 16 | |||||||||
| Equity Value | -102 | |||||||||
| Diluted Shares Outstanding, MM | 133 | |||||||||
| Equity Value Per Share | -0.77 |
What You Will Get
- Real Organogenesis Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Organogenesis Holdings Inc.'s (ORGO) fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Customizable Forecast Inputs: Adjust essential metrics such as revenue growth, EBITDA %, and capital expenditures.
- Instant DCF Valuation: Automatically computes intrinsic value, NPV, and additional outputs in real-time.
- High-Precision Accuracy: Leverages Organogenesis Holdings Inc.'s (ORGO) actual financial data for credible valuation results.
- Simplified Scenario Analysis: Effortlessly evaluate various assumptions and assess results side by side.
- Efficiency Booster: Remove the necessity of constructing intricate valuation models from the ground up.
How It Works
- Download the Template: Gain immediate access to the Excel-based ORGO DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Organogenesis Holdings Inc.'s intrinsic value.
- Test Scenarios: Experiment with different assumptions to assess potential valuation shifts.
- Analyze and Decide: Utilize the results to inform your investment or financial decisions.
Why Choose This Calculator for Organogenesis Holdings Inc. (ORGO)?
- Accurate Data: Utilize real Organogenesis financials for dependable valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the effort of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Designed with an intuitive interface and clear instructions for users of all experience levels.
Who Should Use Organogenesis Holdings Inc. (ORGO)?
- Healthcare Investors: Make informed investment choices with a comprehensive analysis of the regenerative medicine market.
- Market Analysts: Streamline your research with ready-to-use financial models tailored for the biotech sector.
- Consultants: Easily modify reports and presentations to showcase insights on Organogenesis Holdings Inc. (ORGO) for your clients.
- Biotech Enthusiasts: Enhance your knowledge of regenerative medicine and its valuation through practical examples.
- Educators and Students: Utilize it as a valuable resource for learning about healthcare finance and biotechnology in academic settings.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations for Organogenesis Holdings Inc. (ORGO).
- Real-World Data: Historical and projected financials for Organogenesis preloaded for in-depth analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into Organogenesis Holdings Inc. (ORGO).
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable insights.